Related Experiment Video
Updated: Jul 1, 2025

Implantation of Total Artificial Heart in Congenital Heart Disease
Published on: July 18, 2014
Progestogen only contraception in women with congenital heart disease
Francesc Baró-Mariné1, Antonia Pijuan-Domènech2,3, Maria Del Mar Goya1
1Department of Obstetrics and Gynaecology, University Hospital Vall d'Hebron, Barcelona, Spain.
Background:
There is little information of progestogen-only contraceptives in patients with congenital heart disease (CHD) on the long-term.
Objective:
To evaluate the use of contraception in patients with CHD. We studied both short-acting reversible contraceptives (SARCs), oral progestin-only pills (POPs) and long-acting reversible contraceptives (LARCs): intrauterine devices (IUD-IPs) and subdermal implants both impregnated with progestogens (SI-IPs).
Study Design:
Retrospective study of all women attending the preconception clinic. Contraceptive methods were classified in three TIERs of effectiveness before and after consultation. ESC classification regarding pregnancy risk, WHOMEC classification for combined oral contraceptive safety was collected.
Results:
Six hundred and fifty-three patients. A significant proportion of them switched from TIER 3 to TIER 2 or 1 (p < .001) after consultation. One hundred and ninety-nine patients used POPs, 53 underwent IUD-IPs implantation and 36 SI-IPs, mean duration was 58 ± 8, 59 ± 8 and 53 ± 38 months, respectively.
Conclusions:
Because of their safety and efficacy, IUD-IPs and SI-IPs should be considered as first-line contraception in patients with CHD.
Related Concept Videos
Birth Control Methods
Heart Failure Drugs: β-Blockers
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Heart Failure Drugs: Inotropic Agents
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

